drugset / Trial / NCT00710268
Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-03
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 50 mg | Oral |
| Subject | Olaparib | Small molecule | 100 mg | Oral |
| Subject | Olaparib | Small molecule | 200 mg | Oral |
| Subject | Olaparib | Small molecule | 400 mg | Oral |
| Background | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |